ProtoKinetix, Incorporated is a pre-revenue Nevada-based biotech company developing anti-aging glycoprotein (AAGP) technologies for preservation of cells, tissues and organs, holding related IP and facing going-concern risk.

# ProtoKinetix, Incorporated

## Company identity and status
- Nevada corporation; originally incorporated as RJV Network, Inc. on December 23, 1999; name changed to ProtoKinetix, Incorporated on July 8, 2003.
- Focused on research and development of anti-freeze glycoproteins (AFGPs), marketed as anti-aging glycoproteins (AAGPs).
- Headquarters: 109 W Main St, Dalton, Ohio 44618. Phone: (330) 445-4971. Website: www.protokinetix.com.
- Operates as an R&D-stage company with no commercial products on the market.

## Core technology and business focus
- Developing and commercializing AAGP molecules intended to preserve cells, tissues, and organs under stress, including applications in cryopreservation.
- Company reports test results showing AAGP can improve cell recovery from cryopreservation by 30% to 120%.
- Actively collaborating with researchers, advisors, business leaders, and commercial partners to validate AAGP and advance toward commercialization.
- Public development highlight: June 6, 2023 notice regarding a research paper on islet-like cells differentiated from patient-derived iPSCs for Type-1 Diabetes (submitted for publication in Transplantation).

## Intellectual property and licensing
- Holds or licenses technology related to its proprietary AAGP platform.
- Holds previously related technologies assigned from BioKinetix Research, Incorporated (assignment of rights for “superantibodies” in July 2003).
- Primary assets include intellectual property and cash.

## Market and customers
- The company is pre-revenue and has not yet commercialized a product.
- Anticipates relying on collaborations with contract research organizations, universities, and commercial partners for R&D and testing as it advances development.

## Financial snapshot (fiscal year ended December 31, 2025)
- Revenue: $0.
- Net loss from operations: $393,650 (2025); $364,188 (2024).
- Research and development expenses: $106,613 (2025); $99,625 (2024).
- Net operating cash flow: -$135,377 (2025); -$223,050 (2024).
- Primary assets: cash and intellectual property.
- Independent auditors expressed substantial doubt about the company’s ability to continue as a going concern due to recurring losses and negative cash flow and the need for additional financing.

## Operations and facilities
- Principal office: 109 W. Main St, Dalton, Ohio 44618; rent paid month-to-month in 2025.
- Lease for the space is held by The Guzzetta Company LLC; rent was $500 per month in 2024 and 2025.
- No real property ownership.
- Information security and cyber risk management are handled by the CFO and a third-party IT provider.

## People and governance
- As of September 3, 2026, insiders (directors and executive officers) hold approximately 7.83% of voting stock; the heir to the deceased CEO holds approximately 35.8%.
- Management has limited experience operating a public company, which the filing identifies as a potential risk factor.

Summary: ProtoKinetix is a pre-revenue biotech company focused on AAGP technologies, holding related IP and pursuing R&D and collaborations to advance toward commercialization while managing material going-concern risk.

ProtoKinetix, Incorporated is a biotechnology company focused on the research and commercialization of Anti-Freeze Glycoproteins (AAGPs) for applications in healthcare, particularly in cellular preservation.

# Summary of ProtoKinetix, Incorporated

## Overview
ProtoKinetix, Incorporated is a research and development stage biotechnology company dedicated to the scientific study and commercialization of Anti-Freeze Glycoproteins (AFGPs), also known as anti-aging glycoproteins, which are trademarked as AAGPs.

## Business Focus
- **Primary Research Area**: The company focuses on AAGPs, studying their potential applications in healthcare, particularly aimed at preserving cells, tissues, and organs from various stresses.
- **Commercialization Efforts**: ProtoKinetix has been actively working with researchers, business leaders, advisors, and commercial entities to validate and bring AAGPs to market, particularly targeting healthcare solutions.

## Corporate History
- **Incorporation**: The company was incorporated as RJV Network, Inc. in Nevada on December 23, 1999. It transitioned to ProtoKinetix in July 2003 after acquiring proprietary technologies from BioKinetix Research, Inc. for the commercialization of "superantibodies."

## Financials
- **Research and Development Expenses**:
  - 2023: $112,444
  - 2024: $99,625
- **Net Operating Loss**: 
  - 2024: $364,188
  - 2023: $415,479
- **Negative Cash Flow**:
  - 2024: $223,050
  - 2023: $375,989
- **Current Revenue**: The company does not have any revenue as of the latest reporting period.

## Employees and Operations
- **Employee Count**: The document does not specify the exact number of employees at ProtoKinetix.
- **Executive Offices**: The principal executive office is located at 109 W Main St, Dalton, Ohio 44618, and the company operates on a month-to-month rental basis for this space, paying $500 per month.

## Customer Base
- The specific number of customers is not detailed in the document, but the company is actively seeking partnerships with researchers, medical professionals, and potential commercial partners to drive the use of AAGPs in healthcare.

## Key Points
- **R&D Stage**: As a biotechnology firm, ProtoKinetix is in the development phase and has not yet marketed any products.
- **Market Potential**: The company believes there is significant market potential for AAGP in preserving cells, particularly stem cells, but concrete customer numbers are not mentioned.
- **Risk Factors**: The company faces various challenges, including funding acquisition, management retention, regulatory hurdles, and competition from other biotechnology firms. 

Overall, ProtoKinetix, Incorporated is positioned at the intersection of scientific research and commercial application within the biotechnology field, focusing on pioneering advancements in cellular preservation technologies.

ProtoKinetix, Incorporated is a biotechnology company focused on researching and developing Anti-Freeze Glycoproteins (AAGPs) for healthcare applications.

# Company Overview: ProtoKinetix, Incorporated

## Business Focus
ProtoKinetix, Incorporated is a research and development stage biotechnology company that specializes in the scientific research of AFGPs (Anti-Freeze Glycoproteins), also referred to as anti-aging glycoproteins, which are trademarked as **AAGPs®**. The company is actively working on the commercial validation of these glycoproteins, with a focus on various healthcare applications.

## Incorporation and Transition
- **Incorporated:** December 23, 1999, originally as RJV Network, Inc.
- **Name Change:** Changed to ProtoKinetix, Incorporated on July 8, 2003, following an assignment of license agreement with BioKinetix Research, Incorporated for the development of "superantibodies."

## Location and Contact
- **Executive Offices:** 109 W Main St, Dalton, Ohio 44618
- **Phone:** (330) 445-4971
- **Website:** [www.protokinetix.com](http://www.protokinetix.com)

## Financial Performance (as of December 31, 2023)
- **Revenue:** $0 (The company has not generated any revenue from operations.)
- **Research and Development Expenses:**
  - 2023: $112,444
  - 2022: $448,873
- **Net Operating Loss:**
  - 2023: ($415,479)
  - 2022: ($1,907,309)
- **Net Operating Cash Flow:**
  - 2023: ($375,989)
  - 2022: ($804,669)

## Workforce
The company has a **limited number of employees** and is heavily reliant on its management team and consultants, particularly in scientific and developmental capacities. The exact number of employees is not specified in the provided information.

## Collaborations and Research Development
ProtoKinetix relies on **collaborative agreements** with various third parties, including:
- Contract research organizations
- Universities
- Governmental agencies
- Non-profit organizations

These collaborations are critical for the research, development, and testing of its AAGP® technologies. The company has recently submitted a significant research paper related to islet-like cells for Type-1 Diabetes treatment.

## Market Potential
The company is focused on exploring **commercial applications** of AAGPs® in the biotechnology sector, particularly for cell, tissue, and organ preservation. However, it faces challenges in gaining market acceptance and regulatory approvals.

## Conclusion
ProtoKinetix is an early-stage biotechnology company focused on developing potentially revolutionary medical treatments based on anti-freeze glycoproteins, although it currently has no revenue or product sales. The company's financial situation indicates a reliance on future funding to continue operations and research development.

ProtoKinetix, Inc.

10-K / September 3, 2026

10-K / March 28, 2025

10-K / March 20, 2024

10-K / September 3, 2026

ProtoKinetix, Incorporated

Company identity and status

Core technology and business focus

Intellectual property and licensing

Market and customers

Financial snapshot (fiscal year ended December 31, 2025)

Operations and facilities

People and governance